NRD
VRTX icon

Nebula Research & Development’s Vertex Pharmaceuticals VRTX Stock Holding History

Nebula Research & Development’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,775
Closed -$1.3M – 1183
2024
Q2 		$1.3M Buy
+2,775
New +$1.2M 0.21% 144

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Nebula Research & Development's VRTX Position: Q3 2024 in Review

Nebula Research & Development sold out of Vertex Pharmaceuticals (VRTX) in Q3 2024, closing a stake of 2,775 shares — an estimated $1.3M sold.

Nebula Research & Development first reported a position in VRTX in Q2 2024 and held it in 1 quarter. The position peaked at $1.3M in Q2 2024. 1,544 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

  • Nebula Research & Development reported no remaining Vertex Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Nebula Research & Development sold 2,775 Vertex Pharmaceuticals shares in Q3 2024, an estimated $1.3M.
  • Nebula Research & Development first reported a position in Vertex Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Nebula Research & Development's Vertex Pharmaceuticals position peaked at $1.3M in Q2 2024.
  • 1,544 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Nebula Research & Development's 13F filing for Q3 2024, filed 14 Nov 2024.